Trillium Therapeutics Inc. (TRIL) Rating Increased to Hold at Zacks Investment Research
Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “
Several other equities analysts also recently weighed in on the company. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research report on Wednesday, July 5th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $18.00 target price on shares of Trillium Therapeutics in a research report on Friday, June 9th. Finally, HC Wainwright started coverage on Trillium Therapeutics in a research report on Monday, July 17th. They issued a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Trillium Therapeutics currently has an average rating of “Buy” and a consensus price target of $14.95.
Shares of Trillium Therapeutics (NASDAQ TRIL) opened at 5.10 on Tuesday. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $17.70. The company has a 50-day moving average of $4.65 and a 200-day moving average of $5.27. The stock’s market capitalization is $55.05 million.
Several institutional investors have recently made changes to their positions in TRIL. Wells Fargo & Company MN grew its position in shares of Trillium Therapeutics by 34.1% during the first quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock worth $109,000 after buying an additional 4,500 shares in the last quarter. Creative Planning grew its position in shares of Trillium Therapeutics by 1.1% during the second quarter. Creative Planning now owns 26,400 shares of the biotechnology company’s stock worth $116,000 after buying an additional 300 shares in the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Trillium Therapeutics during the second quarter worth about $128,000. K2 Principal Fund L.P. acquired a new position in shares of Trillium Therapeutics during the second quarter worth about $264,000. Finally, Victory Capital Management Inc. grew its position in shares of Trillium Therapeutics by 40.0% during the first quarter. Victory Capital Management Inc. now owns 77,601 shares of the biotechnology company’s stock worth $479,000 after buying an additional 22,171 shares in the last quarter. 47.97% of the stock is owned by institutional investors and hedge funds.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companys lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.
Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.